Printer Friendly

JOHN YOUNG APPOINTED AFFYMETRIX DIRECTOR

 PALO ALTO, Calif., Aug. 18 /PRNewswire/ -- Affymetrix Inc., a subsidiary of Affymax N.V. (NASDAQ: AFMXF), announced today the appointment of John Young to its board of directors. Affymetrix is developing innovative DNA chip systems, based on Affymax VLSIPS(TM) technology, for the clinical diagnostic, biomedical research and emerging genetic analysis markets.
 Young served as president and chief executive officer of Hewlett-Packard Co. for 15 years, retiring in 1992. Hewlett-Packard is an international manufacturer of measurement and computation products and systems used in industry, business, engineering, science, medicine and education. Young serves as a director of Wells Fargo & Co., Chevron Corp. SmithKline Beecham and is a member of The Business Council.
 "John Young's expertise in managing one of the world's most successful, cost-effective high technology instrumentation and information processing companies will be invaluable as we move our products toward commercialization," state John D. Diekman, chairman of the board of Affymetrix.
 Affymetrix has established a board of directors as part of the process of becoming an independent operating company. Affymetrix intends to pursue private financing during 1993.
 The Affymetrix board of directors currently includes:
 -- Paul Berg, Ph.D., director of the Beckman Center for Molecular and Genetic Medicine at the Stanford University School of Medicine
 -- John D. Diekman (chairman), Ph.D., managing director and president of Affymax N.V.
 -- Stephen P.A. Fodor, Ph.D. scientific director of Affymetrix
 -- Vernon R. Loucks Jr., chairman and chief financial officer of Baxter International Inc.
 -- David B. Singer, president and chief executive officer of Affymetrix
 -- Alejandro Zaffaroni, Ph.D., chairman and chief executive officer of Affymax N.V. and co-chairman of ALZA Corp.
 Affymetrix is developing products to enable researchers and clinicians to analyze genetic information rapidly and cost-effectively. Affymetrix is directing its efforts toward the development of very large arrays of DNA probes, or "chips," for the research laboratory and clinical markets. Affymetrix is a wholly owned subsidiary of Affymax N.V. Affymax is developing new technologies to accelerate the pace of drug discovery.
 -0- 8/18/93
 /CONTACT: Diana Kapp of Affymetrix, 415-496-2379/
 (AFMXF)


CO: Affymax N.V.; Affymetrix ST: California IN: MTC SU:

SG-LH -- SJ003 -- 8551 08/18/93 08:31 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Aug 18, 1993
Words:361
Previous Article:WHAT'S THE BEST WAY TO GET A RAISE? -- WORK! SURVEY SHOWS MANAGERS RECOGNIZE EMPLOYEE INITIATIVE
Next Article:CALLER ID DISPLAY UNIT AVAILABLE FOR RENT
Topics:

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters